N
Norihiro Nishimoto
Researcher at Tokyo Medical University
Publications - 188
Citations - 19132
Norihiro Nishimoto is an academic researcher from Tokyo Medical University. The author has contributed to research in topics: Tocilizumab & Rheumatoid arthritis. The author has an hindex of 61, co-authored 187 publications receiving 18010 citations. Previous affiliations of Norihiro Nishimoto include Wakayama Medical University & Juntendo University.
Papers
More filters
Journal ArticleDOI
Structure and function of a new STAT-induced STAT inhibitor
Tetsuji Naka,Masashi Narazaki,Moritoshi Hirata,Tomoshige Matsumoto,Seijiro Minamoto,Atsufumi Aono,Norihiro Nishimoto,Tadahiro Kajita,Tetsuya Taga,Kazuyuki Yoshizaki,Shizuo Akira,Tadamitsu Kishimoto +11 more
TL;DR: It is found that SSI-1 messenger RNA was induced by the cytokines interleukins 4 and 6, leukaemia-inhibitory factor (LIF), and granulocyte colony-stimulating factor (G-CSF), and these findings indicate that SSi-1 is responsible for negative-feedback regulation of the JAK–STAT pathway induced by cytokine stimulation.
Journal ArticleDOI
Pathogenic Significance of Interleukin-6 (IL-6/BSF-2) in Castleman's Disease
Kazuyuki Yoshizaki,Tadashi Matsuda,Norihiro Nishimoto,Taro Kuritani,L Taeho,Katsuyuki Aozasa,T Nakahata,H Kawai,Hiromi Tagoh,Toshihisa Komori +9 more
TL;DR: The findings in this report indicate that the generation of IL-6 by B cells in germinal centers of hyperplastic lymph nodes of Castleman's disease may be the key element responsible for the variety of clinical symptoms in this disease.
Journal ArticleDOI
Treatment of rheumatoid arthritis with humanized anti–interleukin-6 receptor antibody: A multicenter, double-blind, placebo-controlled trial
Norihiro Nishimoto,Kazuyuki Yoshizaki,Nobuyuki Miyasaka,Kazuhiko Yamamoto,Shinichi Kawai,Tsutomu Takeuchi,Jun Hashimoto,Junichi Azuma,Tadamitsu Kishimoto +8 more
TL;DR: Treatment with MRA was generally well tolerated and significantly reduced the disease activity of RA, and the adverse events were not dose dependent.
Journal ArticleDOI
Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial
Shumpei Yokota,Tomoyuki Imagawa,Masaaki Mori,Takako Miyamae,Yukoh Aihara,Shuji Takei,Naomi Iwata,Hiroaki Umebayashi,Takuji Murata,Mari Miyoshi,Minako Tomiita,Norihiro Nishimoto,Tadamitsu Kishimoto +12 more
TL;DR: Tocilizumab is effective in children with systemic-onset juvenile idiopathic arthritis and might be a suitable treatment in the control of this disorder, which has so far been difficult to manage.
Journal ArticleDOI
Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab
Norihiro Nishimoto,Jun Hashimoto,Nobuyuki Miyasaka,Kazuhiko Yamamoto,Shinichi Kawai,Tsutomu Takeuchi,Norikazu Murata,Désirée van der Heijde,Tadamitsu Kishimoto +8 more
TL;DR: Tocilizumab monotherapy was generally well tolerated and provided radiographic benefit in patients with RA and improved signs and symptoms.